Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03943875
Recruitment Status : Recruiting
First Posted : May 9, 2019
Last Update Posted : June 19, 2019
Sponsor:
Collaborator:
Cancer Prevention Research Institute of Texas
Information provided by (Responsible Party):
The University of Texas Medical Branch, Galveston

Brief Summary:
We are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.

Condition or disease Intervention/treatment Phase
Immunization Efficacy Human Papilloma Virus Biological: 9-valent HPV vaccine, 2 dose efficacy Biological: 9-valent HPV vaccine, 3 doses standard timing Phase 4

Detailed Description:
The investigators are studying an amended dosing regimen of an approved drug (Gardasil 9) in the population for which it is approved (vaccine is approved for ages 9-45 years and participants in this study will be 15-26 years of age.) The purpose of the study is to examine a delayed dosing schedule. The current recommendation is to administer the vaccine in 3 doses (administered at 0, 1-2 months and 6 months) to those 15-26 years of age but only 2 doses (0 and 6 months) if given at 9-14 years of age. The investigators will conduct a randomized study to determine if 2 doses will elicit an immune response similar to the standard 3 doses in those 15-26 years of age. Participants in the study group will receive 2 doses of Gardasil 9 at 0 and 6 months. Participants in the control group will receive 3 doses of Gardasil 9 at 0, 1-2 months and 6 months. All participants (Target Accrual n=512) will have 5 mLs of blood drawn at 0, 7, and 12 months. Following the 12 month blood draw, participants randomized to 2-doses will receive the 3rd dose. Potential participants will be recruited in the University of Texas Medical Branch (UTMB) clinics where providers have given the PI permission to directly contact patients. The investigators will also display signs and use email announcements at UTMB and other college campuses and will advertise the study online or by mail. The investigators will call UTMB patients if their provider gave permission to contact the patient, or if the patients gave prior consent to contact through the UTMB system. Potential participants (and their parents, if under 18 years of age) will be screened with inclusion/exclusion criteria. Eligible and interested parents and patients will sign informed written consent. Patients under 18 years of age will sign written assent. At the initial visit, eligible, consented participants will have their blood drawn, be randomized into either the study or control group, and receive a dose of the HPV vaccine. Participants will be re-screened against the inclusion/exclusion criteria at subsequent visits. All participants will receive compensation administered through a ClinCard following each of the 3 blood draws.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 512 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Actual Study Start Date : June 17, 2019
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2023

Arm Intervention/treatment
Active Comparator: Females, 3 dose standard
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
Biological: 9-valent HPV vaccine, 3 doses standard timing
Will be comparison group for 2 dose efficacy group.

Experimental: Females, 2 dose with delayed 3rd dose
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
Biological: 9-valent HPV vaccine, 2 dose efficacy
Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.

Active Comparator: Males, 3 dose standard
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
Biological: 9-valent HPV vaccine, 3 doses standard timing
Will be comparison group for 2 dose efficacy group.

Experimental: Males, 2 dose with delayed 3rd dose
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
Biological: 9-valent HPV vaccine, 2 dose efficacy
Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.




Primary Outcome Measures :
  1. Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 6, measured as number of participants.

  2. Short-term HPV type-specific antibody response for type HPV-11 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 11, measured as number of participants.

  3. Short-term HPV type-specific antibody response for type HPV-16 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 16, measured as number of participants.

  4. Short-term HPV type-specific antibody response for type HPV-18 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 18, measured as number of participants.

  5. Short-term HPV type-specific antibody response for type HPV-31 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 31, measured as number of participants.

  6. Short-term HPV type-specific antibody response for type HPV-33 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 33, measured as number of participants.

  7. Short-term HPV type-specific antibody response for type HPV-45 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 45, measured as number of participants.

  8. Short-term HPV type-specific antibody response for type HPV-52 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 52, measured as number of participants.

  9. Short-term HPV type-specific antibody response for type HPV-58 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 58, measured as number of participants.

  10. HPV type-specific antibody response for type HPV-6 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 6. Measured as number of participants.

  11. HPV type-specific antibody response for type HPV-11 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 11. Measured as number of participants.

  12. HPV type-specific antibody response for type HPV-16 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 16. Measured as number of participants.

  13. HPV type-specific antibody response for type HPV-18 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 18. Measured as number of participants.

  14. HPV type-specific antibody response for type HPV-31 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 31. Measured as number of participants.

  15. HPV type-specific antibody response for type HPV-33 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 33. Measured as number of participants.

  16. HPV type-specific antibody response for type HPV-45 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 45. Measured as number of participants.

  17. HPV type-specific antibody response for type HPV-52 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 52. Measured as number of participants.

  18. HPV type-specific antibody response for type HPV-58 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 58. Measured as number of participants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and females 15-26 years old.
  2. Ability to give informed consent. All participants under 18 years of age must have the informed consent of a parent and must assent to participation.
  3. Has not received any prior doses of the HPV vaccine. We will ask the patient and his/her parent (if <18) about prior vaccination and check the state registry (Immtrac), as well as the UTMB electronic medical record (if previously seen at UTMB), We will check with their primary care provider, if feasible, for patients who are not a previously established UTMB patient.
  4. Identified source of funding for vaccine which may include Texas Vaccines for Children (VFC) program, Medicaid, the Children's Health Insurance Plan (CHIP), Texas Healthy Women program or other public or private health insurance.
  5. Reliable telephone access.
  6. Participant and parent/ guardian (if <18) can read and speak either English or Spanish.

Exclusion Criteria:

  1. For females, currently pregnant or plans to become pregnant or donate eggs in next 12 months. Sexually active females must report that they use regular birth control. All female subjects will be required to take a urine pregnancy test before each Gardasil 9 dose. Any subjects with positive tests will be disqualified from the study and advised to seek prenatal care.
  2. History of 6 or more lifetime sexual partners.
  3. History of any immunodeficiencies (HIV+, chemotherapy treatment, status splenectomy) or autoimmune disorders (lupus, thyroid disorder, psoriasis).
  4. History of bleeding or platelet disorders such as hemophilia.
  5. Currently taking medication which can suppress immune function including systemic corticosteroids, radiation therapy, cyclophosphamide, azathioprine, methotrexate, cyclosporine, leflunomid, TNF-alpha antagonists, monoclonal antibody therapies, or intravenous immunoglobulin treatment.
  6. Known allergies to any components of the vaccine, including aluminum, yeast or Benzonase.
  7. Febrile at ≥100°F in the 24 hours prior to vaccination. This will be reviewed before each Gardasil 9 dose.
  8. Received any non-study inactive vaccines within the past 14 days or any live vaccines within the past 30 days. Those excluded for this reason will be re-screened under the same study number at a later date.
  9. Plan to move out of the Galveston/Houston area in the 13 months following study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03943875


Contacts
Layout table for location contacts
Contact: Abbey B Berenson, MD, PhD 409-772-2417 abberens@utmb.edu
Contact: Christie K Shumate 409-747-5594 ckshumat@utmb.edu

Locations
Layout table for location information
United States, Texas
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555
Contact: Christie K Shumate    409-747-5594    ckshumat@utmb.edu   
Contact: Jacqueline M Hirth, PhD, MPH    409-772-1021    jmhirth@utmb.edu   
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas
Investigators
Layout table for investigator information
Principal Investigator: Abbey B Berenson, MD, PhD University of Texas

Layout table for additonal information
Responsible Party: The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier: NCT03943875     History of Changes
Other Study ID Numbers: 19-0058
RP190022 ( Other Grant/Funding Number: Cancer Prevention & Research Institute of Texas )
First Posted: May 9, 2019    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by The University of Texas Medical Branch, Galveston:
HPV vaccination
Gardasil 9
vaccine efficacy

Additional relevant MeSH terms:
Layout table for MeSH terms
Papilloma
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Vaccines
Immunologic Factors
Physiological Effects of Drugs